Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Publisher's Note: There is a Blood Commentary on this article in this issue.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trněný, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Günter, Humphrey, Kathryn, Stilgenbauer, Stephan, Böttcher, Sebastian, Brüggemann, Monika, Hallek, Michael, Kneba, Michael, van Dongen, Jacques J. M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Letter to Blood
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6356981/
https://ncbi.nlm.nih.gov/pubmed/30455380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-839688
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars